US Stock MarketDetailed Quotes
BMY Bristol-Myers Squibb
- 45.380
- +0.720+1.61%
Trading Jul 25 12:19 ET
91.99BMarket Cap-14638P/E (TTM)
45.970High44.610Low8.35MVolume44.790Open44.660Pre Close378.79MTurnover0.41%Turnover Ratio11.76P/E (Static)2.03BShares60.42052wk High5.58P/B91.82BFloat Cap39.03652wk Low2.34Dividend TTM2.02BShs Float75.683Historical High5.16%Div YieldTTM3.05%Amplitude8.383Historical Low45.377Avg Price1Lot Size
Bristol-Myers Squibb Stock Forum
Sign in to post a comment
$Verizon(VZ.US$ $Cadence Design Systems(CDNS.US$ $NXP Semiconductors(NXPI.US$ $Coca-Cola(KO.US$ $GE Aerospace(GE.US$ $Spotify Technology(SPOT.US$ $Alphabet-A(GOOGL.US$ $Tesla(TSLA.US$ $Visa(V.US$ $Texas Instruments(TXN.US$ $Vertiv Holdings(VRT.US$ $ServiceNow(NOW.US$ $KLA Corp(KLAC.US$ $IBM Corp(IBM.US$ $Chipotle Mexican Grill(CMG.US$ $Ford Motor(F.US$ $AbbVie(ABBV.US$ $American Airlines(AAL.US$ $British American Tobacco(BTI.US$ $Bristol-Myers Squibb(BMY.US$ $3M(MMM.US$
📊⚡️📊
📊⚡️📊
6
1
Dividend stocks haven't been taking off these days, and that's in part due to high interest rates. When investors can get healthy returns from low-risk, interest-paying assets, the case for buying dividend stocks is naturally less appealing. But the good news for long-term investors is that this means stock prices for some solid dividend stocks are low, and there are some enticing deals available right now.
Bristol Myers Squibb $Bristol-Myers Squibb(BMY.US$ , Cisco S...
Bristol Myers Squibb $Bristol-Myers Squibb(BMY.US$ , Cisco S...
+1
77
20
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Bristol-Myers Squibb(BMY.US$
good news with share drops doent understand this share.
good news with share drops doent understand this share.
$Bristol-Myers Squibb (BMY.US)
so many good news. but the share just never go up and yet keep on dropping .
so many good news. but the share just never go up and yet keep on dropping .
1
🔥 3 PDUFA decisions this week! 👇
📌 This week’s PDUFAs:
$Merck & Co(MRK.US$ : 🤔
⇨ Patritumab deruxtecan
‣ Non-small cell lung carcinoma
‣ PDUFA date: 6/26/24 (BLA)
$Verona Pharma(VRNA.US$ : 🤔
⇨ Ensifentrine (Nebulized)
‣ Chronic obstructive pulmonary disease
‣ PDUFA date: 6/26/24 (NDA)
$Genmab(GMAB.US$ : 🤔
⇨ EPKINLY® (Epcoritamab)
‣ Follicular lymphoma
‣ PDUFA date: 6/28/24 (sBLA)
🗓️ Last week’s PDUFAs:
$Merck & Co(MRK.US$ : Approved 6/17 🎉
⇨ CAPVAXIVE (V116)
‣ Pneumo...
📌 This week’s PDUFAs:
$Merck & Co(MRK.US$ : 🤔
⇨ Patritumab deruxtecan
‣ Non-small cell lung carcinoma
‣ PDUFA date: 6/26/24 (BLA)
$Verona Pharma(VRNA.US$ : 🤔
⇨ Ensifentrine (Nebulized)
‣ Chronic obstructive pulmonary disease
‣ PDUFA date: 6/26/24 (NDA)
$Genmab(GMAB.US$ : 🤔
⇨ EPKINLY® (Epcoritamab)
‣ Follicular lymphoma
‣ PDUFA date: 6/28/24 (sBLA)
🗓️ Last week’s PDUFAs:
$Merck & Co(MRK.US$ : Approved 6/17 🎉
⇨ CAPVAXIVE (V116)
‣ Pneumo...
9
$Viking Therapeutics(VKTX.US$ : “I’m a Lilly guy...To go up against Lilly is very, very hard.”
$CAVA Group(CAVA.US$ : “Cava feels like it has the possibility of being a Chipotle. So, even though I know it just had a big spike, I would not abandon it. I would just look to buy more if it came down.”
$Rubrik(RBRK.US$ : “It’s a good company, but the problem is, again, this market hates enterprise software.”
$Forward Air(FWRD.US$ : “There’s g...
$CAVA Group(CAVA.US$ : “Cava feels like it has the possibility of being a Chipotle. So, even though I know it just had a big spike, I would not abandon it. I would just look to buy more if it came down.”
$Rubrik(RBRK.US$ : “It’s a good company, but the problem is, again, this market hates enterprise software.”
$Forward Air(FWRD.US$ : “There’s g...
From YouTube
$Sarepta Therapeutics(SRPT.US$ : ELEVIDYS
$Harmony Biosciences(HRMY.US$ : WAKIX (pitolisant)
$Bristol-Myers Squibb(BMY.US$ : KRAZATI (Adagrasib) + Cetuximab
$argenx SE(ARGX.US$ : VYVGART Hytrulo (Efgartigimod)
$Merck & Co(MRK.US$ : Patritumab deruxtecan
$Verona Pharma(VRNA.US$ : Ensifentrine (Nebulized)
$Rocket Pharmaceuticals(RCKT.US$ : KRESLADI (Marnetegragene autotemcel)
$Harmony Biosciences(HRMY.US$ : WAKIX (pitolisant)
$Bristol-Myers Squibb(BMY.US$ : KRAZATI (Adagrasib) + Cetuximab
$argenx SE(ARGX.US$ : VYVGART Hytrulo (Efgartigimod)
$Merck & Co(MRK.US$ : Patritumab deruxtecan
$Verona Pharma(VRNA.US$ : Ensifentrine (Nebulized)
$Rocket Pharmaceuticals(RCKT.US$ : KRESLADI (Marnetegragene autotemcel)
14
Background and Recent Performance
$Bristol-Myers Squibb(BMY.US$ is a global biopharmaceutical company known for its innovative treatments in oncology, immunology, and cardiovascular diseases. Over the past year, BMY has faced some challenges, with its stock price nearing its 52-week low. As of June 20, 2024, the stock is trading at $40.795, which is close to its 52-week low of around $40.00.
$Bristol-Myers Squibb(BMY.US$
Despite recent performance s...
$Bristol-Myers Squibb(BMY.US$ is a global biopharmaceutical company known for its innovative treatments in oncology, immunology, and cardiovascular diseases. Over the past year, BMY has faced some challenges, with its stock price nearing its 52-week low. As of June 20, 2024, the stock is trading at $40.795, which is close to its 52-week low of around $40.00.
$Bristol-Myers Squibb(BMY.US$
Despite recent performance s...
15
$Bristol-Myers Squibb(BMY.US$
FDA Approves Augtyro (repotrectinib) 🎉
⇨ next-gen. Tyrosine Kinase Inhibitor (TKI) ⚛️
⇨ the only FDA-approved treatment for NTRK-positive tumors 👏
⇨ accelerated approval (sNDA) marks its 2nd indication in the US
⇨ based on Ph1/2 TRIDENT-1 trial 🧫
» effective in both TKI-naïve & TKI-pretreated patients across solid tumors
» showed significant response rates
FDA Approves Augtyro (repotrectinib) 🎉
⇨ next-gen. Tyrosine Kinase Inhibitor (TKI) ⚛️
⇨ the only FDA-approved treatment for NTRK-positive tumors 👏
⇨ accelerated approval (sNDA) marks its 2nd indication in the US
⇨ based on Ph1/2 TRIDENT-1 trial 🧫
» effective in both TKI-naïve & TKI-pretreated patients across solid tumors
» showed significant response rates
5
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
10baggerbamm : big day Wednesday hopefully we see I knock the cover off the ball moment exceed whisper number exceed revenue number and exceed forward guidance expectations if we can achieve that it's over 100 bucks